Letter |

Global health groups appeal to congress: Fix the FDA PRV for neglected diseases

Photograph by Alexis Huguet

Letter from American Thoracic Society, Drugs for Neglected Diseases initiative, HIV Medicine Association, Infectious Diseases Society of America, Médecins Sans Frontières/Doctors Without Borders USA, TB Alliance, and Treatment Action Group to request US Congress to amend the Food and Drug Administration (FDA) Priority Review Voucher (PRV) program for neglected diseases.

Amendments could help ensure that the program effectively accomplishes its goal of incentivizing new research and development (R&D) for neglected diseases, and that new neglected disease products brought to market through the PRV program are made accessible and affordable to those who need them.

/